Exagen
XGN
31 hedge funds and large institutions have $16.5M invested in Exagen in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 19 reducing their positions, and 10 closing their positions.
8,400% more call options, than puts
Call options by funds: $170K | Put options by funds: $2K
6.27% less ownership
Funds ownership: 48.77% → 42.5% (-6.3%)
18% less funds holding
Funds holding: 38 → 31 (-7)
23% less capital invested
Capital invested by funds: $21.4M → $16.5M (-$4.96M)
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
74% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$810K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$12.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.7K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$2.57K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$1.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.06M |
| 2 |
CAC
Cowen and Company
New York
|
-$932K |
| 3 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$269K |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$223K |
| 5 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
-$220K |
XGN Hedge Fund Activity: Q4 2022 in Review
31 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q4 2022, worth a combined $16.5M — down 23% from $21.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of XGN and 3 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 5 added.
The largest buyer was RTW Investments, adding an estimated $810K. The largest seller was Stonepine Capital Management, cutting an estimated $1.06M.
- 31 institutional investors held Exagen (XGN) as of Q4 2022, down from 38 in Q3 2022.
- Funds reported $16.5M of Exagen stock for Q4 2022, down 23% quarter-over-quarter.
- 3 funds opened new Exagen positions in Q4 2022 and 10 closed out, a net change of -7 holders.
- The largest Exagen buyer in Q4 2022 was RTW Investments, an estimated $810K added.
- The largest Exagen seller in Q4 2022 was Stonepine Capital Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q4 2022.